EGFR and esophageal squamous cell carcinoma: Targeted therapy may not always have any observable effect on 18F-FDG uptake; however, this study shows the feasibility of 18F-FDG-PET as an early PD biomarker of anti-HER1 therapy in ESCC xenograft models.